Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Influenza vaccination: protecting the most vulnerable.

Authors:
Alex R Tanner Robert B Dorey Nathan J Brendish Tristan W Clark

Eur Respir Rev 2021 Mar 13;30(159). Epub 2021 Jan 13.

School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

Influenza virus infection causes seasonal epidemics and occasional pandemics, leading to huge morbidity and mortality worldwide. Vaccination against influenza is needed annually as protection from constantly mutating strains is required. Groups at high risk of poor outcomes include the elderly, the very young, pregnant women and those with chronic health conditions. However, vaccine effectiveness in the elderly is generally poor due to immunosenescence and may be altered due to "original antigenic sin". Strategies to overcome these challenges in the elderly include high-dose or adjuvant vaccines. Other options include vaccinating healthcare workers and children as this reduces community-level influenza transmission. Current guidelines in the UK are that young children receive a live attenuated nasal spray vaccine, adults aged >65 years receive an adjuvanted trivalent inactivated vaccine and adults aged <65 years with comorbidities receive a quadrivalent inactivated vaccine. The goal of a universal influenza vaccine targeting conserved regions of the virus and avoiding the need for annual vaccination is edging closer with early-phase trials under way.

Download full-text PDF

Source
http://dx.doi.org/10.1183/16000617.0258-2020DOI Listing
March 2021

Publication Analysis

Top Keywords

vaccine adults
8
adults aged
8
"original antigenic
4
antigenic sin"
4
altered "original
4
immunosenescence altered
4
poor immunosenescence
4
sin" strategies
4
high-dose adjuvant
4
challenges elderly
4
elderly include
4
overcome challenges
4
strategies overcome
4
generally poor
4
include high-dose
4
influenza
4
young pregnant
4
pregnant women
4
elderly young
4
include elderly
4

Keyword Occurance

Similar Publications

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.

Authors:
Tracy J Ruckwardt Kaitlyn M Morabito Emily Phung Michelle C Crank Pamela J Costner LaSonji A Holman Lauren A Chang Somia P Hickman Nina M Berkowitz Ingelise J Gordon Galina V Yamshchikov Martin R Gaudinski Bob Lin Robert Bailer Man Chen Ana M Ortega-Villa Thuy Nguyen Azad Kumar Richard M Schwartz Lisa A Kueltzo Judith A Stein Kevin Carlton Jason G Gall Martha C Nason John R Mascola Grace Chen Barney S Graham

Lancet Respir Med 2021 Apr 14. Epub 2021 Apr 14.

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address:

Background: Multiple active vaccination approaches have proven ineffective in reducing the substantial morbidity and mortality caused by respiratory syncytial virus (RSV) in infants and older adults (aged ≥65 years). A vaccine conferring a substantial and sustainable boost in neutralising activity is required to protect against severe RSV disease. To that end, we evaluated the safety and immunogenicity of DS-Cav1, a prefusion F subunit vaccine. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

The willingness to accept the COVID-19 vaccine and affecting factors among healthcare professionals: A cross-sectional study in Turkey.

Authors:
Askin Keskin Kaplan Mustafa Kursat Sahin Hulya Parildar Isil Adadan Guvenc

Int J Clin Pract 2021 Apr 16:e14226. Epub 2021 Apr 16.

Bakircay University, Faculty of Medicine, Cigli Training and Research Hospital, Department of Otolaryngology - Izmir, Turkey.

Introduction: While discussions on the effectiveness of COVID-19 vaccines continue, healthcare professionals' attitudes and their growing fear and anxiety during the pandemic process are not yet fully known. In this study, we aimed to investigate the COVID-19 vaccine acceptance and affecting factors in healthcare professionals.

Methods: This was a cross-sectional online survey conducted in 1574 healthcare professionals consisting of physicians, nurses, dentists, pharmacists, and healthcare personnel in Turkey in December 2020. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Using chaos indicators to determine vaccine influence on epidemic stabilization.

Authors:
André F Steklain Ahmed Al-Ghamdi Euaggelos E Zotos

Phys Rev E 2021 Mar;103(3-1):032212

Department of Physics, School of Science, Aristotle University of Thessaloniki, 541 24, Thessaloniki, Greece.

Virus outbreaks have the potential to be a source of severe sanitarian and economic crisis. We propose a new methodology to study the influence of several parameter combinations on the dynamical behavior of simple epidemiological compartmental models. Using this methodology, we analyze the behavior of a simple vaccination model. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.

Authors:
Kawsar R Talaat Cristina Alaimo Patricia Martin A Louis Bourgeois Anita M Dreyer Robert W Kaminski Chad K Porter Subhra Chakraborty Kristen A Clarkson Jessica Brubaker Daniel Elwood Rahel Frölich Barbara DeNearing Hailey Weerts Brittany L Feijoo Jane Halpern David Sack Mark S Riddle Veronica Gambillara Fonck

EBioMedicine 2021 Apr 13;66:103310. Epub 2021 Apr 13.

LimmaTech Biologics AG, Schlieren, Switzerland.

Background: Shigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income countries. The Flexyn2a vaccine conjugates the O-polysaccharide of Shigella flexneri 2a to Pseudomonas aeruginosa exotoxin A. We describe a Phase 2b proof-of-concept challenge study that evaluated safety, immunogenicity, and efficacy of the Flexyn2a vaccine to protect against shigellosis. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study.

Authors:
Simon C Mendelsohn Andrew Fiore-Gartland Adam Penn-Nicholson Humphrey Mulenga Stanley Kimbung Mbandi Bhavesh Borate Katie Hadley Chris Hikuam Munyaradzi Musvosvi Nicole Bilek Mzwandile Erasmus Lungisa Jaxa Rodney Raphela Onke Nombida Masooda Kaskar Tom Sumner Richard G White Craig Innes William Brumskine Andriëtte Hiemstra Stephanus T Malherbe Razia Hassan-Moosa Michèle Tameris Gerhard Walzl Kogieleum Naidoo Gavin Churchyard Thomas J Scriba Mark Hatherill

Lancet Glob Health 2021 Apr 13. Epub 2021 Apr 13.

South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. Electronic address:

Background: A rapid, blood-based triage test that allows targeted investigation for tuberculosis at the point of care could shorten the time to tuberculosis treatment and reduce mortality. We aimed to test the performance of a host blood transcriptomic signature (RISK11) in diagnosing tuberculosis and predicting progression to active pulmonary disease (prognosis) in people with HIV in a community setting.

Methods: In this prospective diagnostic and prognostic accuracy study, adults (aged 18-59 years) with HIV were recruited from five communities in South Africa. Read More

View Article and Full-Text PDF
April 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap